peoplePerson
Matthew D. Galsky
Led trials that brought immunotherapy into bladder cancer and tested skipping cystectomy in responders.
Genitourinary oncologist who led IMvigor130 and studies of chemo-immunotherapy with bladder preservation in muscle-invasive disease.
Role
Director, Genitourinary Medical Oncology; Co-Director, Center of Excellence for Bladder Cancer
Specialisms
Bladder cancerImmunotherapyBladder preservation
Profiles
| Title | Journal | Year |
|---|---|---|
| Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130) | Lancet | 2020 |